A phase II study of VP-16-fosfamide-cisplatin combination chemotherapy plus early concurrent thoracic irradiation for previously untreated limited small cell lung cancer.

MLA

Woo, I. S., et al. “A Phase II Study of VP-16-Fosfamide-Cisplatin Combination Chemotherapy plus Early Concurrent Thoracic Irradiation for Previously Untreated Limited Small Cell Lung Cancer.” Japanese Journal of Clinical Oncology, vol. 30, no. 12, Dec. 2000, pp. 542–46. EBSCOhost, https://doi.org/10.1093/jjco/hyd135.

APA

Woo, I. S., Park, Y. S., Kwon, S. H., Park, Y. L., Lee, J. A., Park, M. J., Hyun, I. G., Jung, K. S., Bae, H. S., Oh, D. H., Kim, W. S., Park, K., Park, C. H., Kim, H. J., & Ahn, Y. C. (2000). A phase II study of VP-16-fosfamide-cisplatin combination chemotherapy plus early concurrent thoracic irradiation for previously untreated limited small cell lung cancer. Japanese Journal of Clinical Oncology, 30(12), 542–546. https://doi.org/10.1093/jjco/hyd135

Chicago

Woo, I S, Y S Park, S H Kwon, Y L Park, J A Lee, M J Park, I G Hyun, et al. 2000. “A Phase II Study of VP-16-Fosfamide-Cisplatin Combination Chemotherapy plus Early Concurrent Thoracic Irradiation for Previously Untreated Limited Small Cell Lung Cancer.” Japanese Journal of Clinical Oncology 30 (12): 542–46. doi:10.1093/jjco/hyd135.